Gene Polymorphisms in Cardiovascular Disease and Cancer

2019

Dr. Nalbantoglu's research and teaching focus on systems and molecular medicine, including omics-based clinical biomarkers for precision oncology and autoinflammation. She holds a TUBITAK R&D Women Entrepreneur Innovation Award, and works as principal investigator, senior researcher, and co-investigator of several partnering projects; she also supervises MSc and PhD students. She publishes her work in peer-reviewed national and international journals, and has authored/coauthored book chapters and conference proceedings. In addition, she has presented national/international invited talks, and has been a reviewer for many scientific journals.

2020

Even if cancer and cardiovascular diseases are considered two distinct diseases, an intricate interconnection between these conditions has been established. Increased risk of malignancy has been identified in patients with cardiovascular disease, as well as a greater propensity to the development of cardiovascular diseases has been observed in patients with cancer. The development of cardiotoxicity following exposure to certain anticancer drugs only partially explains this relationship. Shared risk factors and common pathogenic mechanisms suggest the existence of a common biology and a complex interplay between these two conditions. Due to improving longevity and therapeutic advances, the number of patients affected or potentially at risk of developing these two diseases is constantly increasing and currently, several drugs against cancer from anthracyclines to checkpoint inhibitors, can also cause a wide range of unexpected cardiovascular side effects. Management of these issues in...

2000

Cancer Research, 2000

The AACR-Pezcoller International Award for Cancer Research is given annually to a scientist anywhere in the world who has made a major scientific discovery in the field of cancer, who continues to be active in the field, and whose ongoing work holds promise for future substantive contributions to cancer research. The Award recognizes extraordinary basic or translational cancer research. The Award will be presented to a single investigator for his or her highly original work. Under extraordinary circumstances, two individuals may be selected to share the Award when their investigations are clearly related and have resulted in prizeworthy work. The Awardee will be selected by an international committee of AACR members appointed by the AACR President with the agreement of the Council of the Pezcoller Foundation. The selection will be based solely on the Awardee's scientific accomplishments without regard to race, gender, nationality, geographic location, or religious or political views. The Pezcoller Foundation was established in 1982 by Professor Alessio Pezcoller, a dedicated Italian surgeon who has made important contributions to medicine throughout his career and who, through his foresight, vision, and generous gift in support of the formation of the Foundation, stimulated others to make significant advances in cancer research. Over the past decade the Pezcoller Foundation, in collaboration with the E.S.O.-European School of Oncology, gave a major biennial award for outstanding contributions to cancer and cancer-related biomedical science. The American Association for Cancer Research (AACR) was founded in 1907 by eleven physicians and scientists dedicated to the conquest of cancer and now has over 15,000 members in more than 60 countries who are experts in basic, clinical, and translational cancer research. The AACR is dedicated to its mission of preventing and curing cancer through the communication of important scientific results in a variety of forums including publications, meetings, and training and educational programs. Because of the commitment of the Foundation and the AACR to scientific excellence in cancer research, these organizations are now collaborating annually on the presentation of this Award. This will strengthen international collaborations and will be a catalyst for advancements in cancer research internationally.

Expert Opinion on Investigational Drugs, 2001

Considerable variety in how patients respond to treatments, driven by differences in their geno-and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer's perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients.

British Journal of Clinical Pharmacology, 2001

Cancer Causes & Control, 2015

Use of Human Genome Organisation (HUGO) Gene Nomenclature Committee (HGNC)-approved symbols for genes and gene products: We use symbols approved by HGNC and described at www.genenames.org; those include BRAF, CD274, ERBB2, ESR1, FASN, KRAS, MLH1, PDCD1LG2, PGR, PIK3CA, and VHL. Gene names are italicized while names of gene products are nonitalicized. Non-official names are described in parenthesis where helpful.

Annals of Oncology, 2008

JNCI Journal of the National Cancer Institute, 2010

Recent advances in genomic research have demonstrated a substantial role for genomic factors in predicting response to cancer therapies. Researchers in the fields of cancer pharmacogenomics and pharmacoepidemiology seek to understand why individuals respond differently to drug therapy, in terms of both adverse effects and treatment efficacy. To identify research priorities as well as the resources and infrastructure needed to advance these fields, the National Cancer Institute (NCI) sponsored a workshop titled "Cancer Pharmacogenomics: Setting a Research Agenda to Accelerate Translation" on July 21, 2009, in Bethesda, MD. In this commentary, we summarize and discuss five science-based recommendations and four infrastructurebased recommendations that were identified as a result of discussions held during this workshop. Key recommendations include 1) supporting the routine collection of germline and tumor biospecimens in NCI-sponsored clinical trials and in some observational and population-based studies; 2) incorporating pharmacogenomic markers into clinical trials; 3) addressing the ethical, legal, social, and biospecimen-and data-sharing implications of pharmacogenomic and pharmacoepidemiologic research; and 4) establishing partnerships across NCI, with other federal agencies, and with industry. Together, these recommendations will facilitate the discovery and validation of clinical, sociodemographic, lifestyle, and genomic markers related to cancer treatment response and adverse events, and they will improve both the speed and efficiency by which new pharmacogenomic and pharmacoepidemiologic information is translated into clinical practice.